Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

The effects of estrogen deficiency and bisphosphonate treatment on tissue mineralisation and stiffness in an ovine model of osteoporosis.

Brennan O, Kennedy OD, Lee TC, Rackard SM, O'Brien FJ, McNamara LM.

J Biomech. 2011 Feb 3;44(3):386-90. doi: 10.1016/j.jbiomech.2010.10.023. Epub 2010 Nov 20.

PMID:
21093863
2.

Effects of estrogen deficiency and bisphosphonate therapy on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis.

Brennan O, Kennedy OD, Lee TC, Rackard SM, O'Brien FJ.

J Orthop Res. 2011 Mar;29(3):419-24. doi: 10.1002/jor.21229. Epub 2010 Sep 30.

3.

Effects of ageing, prolonged estrogen deficiency and zoledronate on bone tissue mineral distribution.

Brennan MA, Gleeson JP, O'Brien FJ, McNamara LM.

J Mech Behav Biomed Mater. 2014 Jan;29:161-70. doi: 10.1016/j.jmbbm.2013.08.029. Epub 2013 Sep 14.

PMID:
24090875
4.

Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.

Hornby SB, Evans GP, Hornby SL, Pataki A, Glatt M, Green JR.

Calcif Tissue Int. 2003 Apr;72(4):519-27. Epub 2003 Feb 10.

PMID:
12574877
5.

Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid.

Glatt M, Pataki A, Evans GP, Hornby SB, Green JR.

Osteoporos Int. 2004 Sep;15(9):707-15. Epub 2004 Mar 13.

PMID:
15024556
6.

Site specific increase in heterogeneity of trabecular bone tissue mineral during oestrogen deficiency.

Brennan MA, Gleeson JP, Browne M, O'Brien FJ, Thurner PJ, McNamara LM.

Eur Cell Mater. 2011 May 15;21:396-406.

7.

Biomechanical properties across trabeculae from the proximal femur of normal and ovariectomised sheep.

Brennan O, Kennedy OD, Lee TC, Rackard SM, O'Brien FJ.

J Biomech. 2009 Mar 11;42(4):498-503. doi: 10.1016/j.jbiomech.2008.11.032. Epub 2009 Jan 25.

PMID:
19171344
8.

A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats.

Gasser JA, Green JR, Shen V, Ingold P, Rebmann A, Bhatnagar AS, Evans DB.

Bone. 2006 Oct;39(4):787-95. Epub 2006 Jul 17.

PMID:
16844441
9.

Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.

Tanaka M, Mori H, Kayasuga R, Ochi Y, Kawada N, Yamada H, Kishikawa K.

Bone. 2008 Nov;43(5):894-900. doi: 10.1016/j.bone.2008.07.002. Epub 2008 Jul 18.

PMID:
18687415
10.

Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice.

Liu J, Xu K, Wen G, Guo H, Li S, Wu X, Dai R, Sheng Z, Liao E.

Bone. 2008 May;42(5):950-9. doi: 10.1016/j.bone.2008.01.010. Epub 2008 Feb 8.

PMID:
18337202
11.

The effect of bone morphometric changes on orthodontic tooth movement in an osteoporotic animal model.

Hashimoto M, Hotokezaka H, Sirisoontorn I, Nakano T, Arita K, Tanaka M, Yoshida N.

Angle Orthod. 2013 Sep;83(5):766-73. doi: 10.2319/111312-869.1. Epub 2013 Feb 27.

PMID:
23445276
12.

Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid.

Gamsjaeger S, Buchinger B, Zwettler E, Recker R, Black D, Gasser JA, Eriksen EF, Klaushofer K, Paschalis EP.

J Bone Miner Res. 2011 Jan;26(1):12-8. doi: 10.1002/jbmr.180.

13.

Bone degeneration and recovery after early and late bisphosphonate treatment of ovariectomized wistar rats assessed by in vivo micro-computed tomography.

Brouwers JE, Lambers FM, Gasser JA, van Rietbergen B, Huiskes R.

Calcif Tissue Int. 2008 Mar;82(3):202-11. doi: 10.1007/s00223-007-9084-3. Epub 2008 Feb 20.

14.

Effect of zoledronate acid treatment on osseointegration and fixation of implants in autologous iliac bone grafts in ovariectomized rabbits.

Qi M, Hu J, Li J, Li J, Dong W, Feng X, Yu J.

Bone. 2012 Jan;50(1):119-27. doi: 10.1016/j.bone.2011.10.011. Epub 2011 Oct 17.

PMID:
22023930
15.

Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat.

Gasser JA, Ingold P, Venturiere A, Shen V, Green JR.

J Bone Miner Res. 2008 Apr;23(4):544-51.

16.

Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis.

Little DG, Smith NC, Williams PR, Briody JN, Bilston LE, Smith EJ, Gardiner EM, Cowell CT.

J Bone Miner Res. 2003 Jul;18(7):1300-7.

17.

In search of an animal model for postmenopausal diseases.

Thorndike EA, Turner AS.

Front Biosci. 1998 Apr 16;3:c17-26. Review.

18.

Does exercise modify the effects of zoledronic acid on bone mass, microarchitecture, biomechanics, and turnover in ovariectomized rats?

Lespessailles E, Jaffré C, Beaupied H, Nanyan P, Dolléans E, Benhamou CL, Courteix D.

Calcif Tissue Int. 2009 Aug;85(2):146-57. doi: 10.1007/s00223-009-9269-z. Epub 2009 Jul 17.

PMID:
19609736
19.

Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis.

Simm PJ, Johannesen J, Briody J, McQuade M, Hsu B, Bridge C, Little DG, Cowell CT, Munns CF.

Bone. 2011 Nov;49(5):939-43. doi: 10.1016/j.bone.2011.07.031. Epub 2011 Jul 28.

PMID:
21820091
20.

Glucocorticoid treatment of ovariectomized sheep affects mineral density, structure, and mechanical properties of cancellous bone.

Schorlemmer S, Gohl C, Iwabu S, Ignatius A, Claes L, Augat P.

J Bone Miner Res. 2003 Nov;18(11):2010-5.

Items per page

Supplemental Content

Write to the Help Desk